1. Introduction {#sec1-1}
===============

Human lymphomas, aggressive malignant disorders, are categorized into the Hodgkin and non-Hodgkin lymphoma (NHL) according to World Health Organization (WHO) ([@ref14]; [@ref25]). NHL includes several histologically and biologically different lymphoid malignancies, which currently are less divulged with possibly distinct etiologies ([@ref5]). It is estimated that there were approximately 70800 new cases of NHL leading to 18990 deaths, making up for an about 4% of new cancer diagnoses and 3% of cancer deaths, in the USA ([@ref24]). Roughly 85% of NHL cases show a B-cell origin. Most common subcategories of NHL include aggressive diffuse large B-cell lymphoma (DLBCL), indolent follicular lymphoma (FL), and mantle cell lymphoma (MCL) ([@ref23]; [@ref25]). The balanced translocations ([@ref4]) in NHL show distinct disease entities ([@ref12]; [@ref1]). Therefore, assessment of such lesions should include a more precise diagnosis and a risk-based treatment.

Cytogenetic analyses demonstrated that there is a close association between MCL and t (11; 14) (q13; q32) ([@ref17]; [@ref29]). The translocation juxtaposes sequence of Ig heavy chain gene (IGH) with the BCL*-*1 locus, which results in the CCND1 gene up-regulation and, in turn, cyclin D1 overexpression ([@ref21]; [@ref7]; [@ref7]); although concordancy was not shown between overexpression of cyclin D1 and t (11; 14) (q13; q32) in MCL cases ([@ref17]; [@ref29]). Such discrepancy can be due to a low mitotic index of malignant cells and the metaphase spreads' poor morphology. Additionally, cytogenetic assessment is a time-consuming method, especially, in the assessment of lymphoma samples ([@ref18]). Other molecular methods show their own restriction scattering 11q13 breakpoints. Morphological features along with immunopathological assessments are now routinely, the principle of diagnosis in neoplastic lymphoma, whereas, the availability of BIOMED-2 protocol further enhances our ability to diagnose and classify lymphoid malignancies.

Currently, the BIOMED-2 multiplex PCR methods, based on clonality assays, are being widely applied in the diagnosis of suspected lymphoproliferative disorders (LPD). Thus, in this study, we applied the BIOMED-2 PCR protocol to evaluate the rate of CCND1-IGH fusion in NHL patients in order to improve the NHL detection.

2. Materials and Methods {#sec1-2}
========================

Samples including 100 formalin-fixed paraffin-embedded (FFPE) blocks were obtained from the archives of the Department of Pathology at Cancer Institute of Imam Khomeini Hospital, Tehran, Iran. And, the analyses were carried out at Tabriz University of Medical Sciences. The pathological board re-assessed all samples and confirmed the diagnosis based on WHO classification criteria. Informed consent had been obtained from each participant and the utilized protocol was approved by the ethic committee, which was in compliance with the Helsinki declaration. As controls, tonsil tissue and IVS-0010 (5%) control clonal DNA (InvivoScribe; catalog No. 4-088-0590) used as positive sample. Three or four 5-micron sections of the samples were obtained from each FFPE tissue, transferred into sterile containers and stored at room temperature. Thereafter, DNA was extracted as described by manufacturer's protocol (Quick Extract kit, UK). Briefly, all the samples incubated at 98 °C for 2 min followed by 56 °C for 1 h in 1.5 ml sterile tubes containing 100 μl of extraction kit solution. Tubes were shaken every 30 min. The samples were then centrifuged at 8870 g for 10 min. Finally, collected samples were stored at -20 °C. In order to evaluate the quality and quantity of the extracted DNA, all samples were quantified by UV spectrophotometry at 260/280 nm (using the NanoDrop TM ND-1,000, NanoDrop Technology, Wilmington, DE, USA). The average concentration of all DNA and OD260/280 ratio were 150 ng/μl and 1.85, respectively.

For the detection of t (11; 14) translocations, based on BIOMED-2 protocol, a pair of primers ([Table 1](#T1){ref-type="table"}) was used for PCR amplification.

###### 

Primers used for the PCR amplification

  Name           Sequence
  -------------- ------------------------------
  Bcl1/MTC       5' GGATAAAGGCGAGGAGCATAA 3'
  JH consensus   3' CCAGTGGCAGAGGAGTCCATTC 5'

For determination of breakpoint at cluster region, PCR were carried out on the extracted DNA of the tested samples, negative and positive controls. The PCR reactions were in a final volume of 25μl containing 150 ng genomic DNA, 1 pmol of each primer, and 14 μlred master mix (Ampliqon, Denmark). Amplification program was initiated with pre-incubation at 95°C for 10 min, followed by 35 cycles of 30 s at 95°C, 50 s at 60°C, and 90 s at 72°C. After the final cycle, a post-extension step was performed for 10 min at 72°C. Subsequently, PCR products were directly loaded on the agarose gel (1.5%) and stained with ethidium bromide.

3. Results {#sec1-3}
==========

PCR amplification assay was performed with a pair of primers to rapidly identifyCCND1-IGH fusion genes stemming from breakpoints in MTC. If additional bands except the control fragment were amplified, PCR assays would be carried out. This reaction detected MTC breakpoints. Thus, amplification only identified a CCND1-IGH fusion. A total of 100 lymph node cases that consisted of 89 DLBCL cases including 15 cases less than 18 years old and 11 cases of MCL were identified. Patients ages ranged between 13 to 91 years old at the time of diagnosis (mean 50.95 years). The patients included 63% males and 37% females.

Out of 100 cases, 19 cases (19%) were observed to carry a concurrent translocation involving BCL-1 based on PCR analysis using BIOMED-2 protocol. There was a significant association between BCL-1 gene rearrangements and the lymphomas in the patients older than 55 years (P\<0.05). Gender was not significantly associated with BCL-1 gene rearrangements (P\>0.05). There was not significant association between DLBCL lymphoma patients under 18 years old and BCL-1 gene rearrangement (P\>0.05).

While investigating the two markers, 80% (80/100) of the cases were positive and 20% (20/100) of cases were negative for CD20. In addition, the positive and negative expressions of LCA/CD45 marker were 76% (76/100) and 26% (26/100), respectively.

###### 

Immunohistochemical and clinicopathological features of 19 patients with BCL-1 gene rearrangements

  ID          Age at Diagnosis   Sex   Histological Type   CD20   LCA/CD45
  ----------- ------------------ ----- ------------------- ------ ----------
  **M3-1**    61                 F     DLBCL               \+     \-
  **M3-2**    73                 F     MCL                 \+     \+
  **M3-3**    59                 M     MCL                 \+     \+
  **M3-5**    62                 M     DLBCL               \+     \-
  **M3-6**    74                 F     DLBCL               \-     \+
  **M3-10**   57                 F     MCL                 \+     \+
  **M3-11**   70                 M     MCL                 \-     \+
  **M3-12**   13                 M     DLBCL               \+     \+
  **M3-13**   70                 F     DLBCL               \_     \+
  **M3-17**   45                 M     MCL                 \+     \-
  **M3-24**   75                 F     DLBCL               \_     \-
  **M3-26**   50                 M     MCL                 \_     \+
  **M3-34**   70                 M     MCL                 \+     \-
  **M3-39**   71                 M     DLBCL               \+     \+
  **M3-40**   67                 M     DLBCL               \+     \-
  **M3-66**   62                 F     DLBCL               \-     \+
  **M3-68**   59                 F     DLBCL               \-     \+
  **M3-70**   22                 F     DLBCL               \+     \+
  **M3-71**   48                 M     DLBCL               \-     \-

4. Discussion {#sec1-4}
=============

There is an increasing amount of literature demonstrating that balanced translocations are available in a large and heterogeneous number in NHL. Lymphoid cells experience surface antigen receptor gene rearrangements over immune cell system differentiation. Nevertheless, tumor cells showed identical immunoglobulin gene rearrangements patterns based on the origin of B, T, and NK cells in lymphoid malignancies ([@ref28]; [@ref9]; [@ref16]; [@ref13]; [@ref16]; [@ref22]). Mantle cell lymphoma (MCL), which refers to a different type of B-cell lymphoma, is t(11;14) translocation and cyclin D1 overexpression ([@ref3]). Furthermore, various translocations were shown in smaller fractions of individuals with lymphoma involving C-MYC/IGH (t(8;14)(q24;q32)), IGK/C-MYC (t(2;8)(p12;q24)), and C-MYC/IGL (t(8;22)(q24;q11)) in Burkitt lymphoma, API-2/MLT (t(11;18)(q21;q21)) and BCL-10/IGH (t(1;14)(p22;q32)) in MALT lymphoma, BCL-6/VARIOUS (t(3;Var)(q27;Var)) and IGH/BCL-8 (t(14;15)(q32;q11-13)) in DLCL, ALK/NPM-1 (t(2;5)(p23;q35)) in anaplastic large cell lymphoma, and PAX-5/IGH(t(9;14)(p13;q32)) in LL ([@ref19]).

FISH and PCR are molecular cytogenetic techniques for assessment of these translocations particularly t(11;14)(q13;q32) with formation of the fusion oncogene IgH/BCL1 in MCL lymphomas ([@ref6]). In spite of the fact that PCR is the most sensitive and specific molecular technique to determine genetic aberrations through chromosome rearrangements, FFPE tissue samples are known to be a reliable source of DNA for molecular assessment ([@ref26]).

We previously reported that the BIOMED-2 protocol could be considered reliable for clonality detection, especially in IGH analysis on FFPE in lymphoid malignancies ([@ref20]). We also found that the complete IGH and incomplete IGH D-J clonality gene rearrangement assays using BIOMED-2 protocols may be valuable for detection of clonal gene rearrangements, especially in HL cases ([@ref10]). IGH and IGK rearrangement based upon BIOMED-2 protocol enhanced clonality detection rate (up to 25% of cases) in lymphoma malignancies ([@ref27]; [@ref11]). We described a molecular method for effective identification of CCND1-IGH fusion in DLBCL ([@ref11]).

In this study, 100 paraffin embedded lymph node specimens were analyzed for the t(11;14) Bcl-1 gene rearrangement using PCR to detect the t(11;14) translocation by one pair of primers specific for the MTC breakpoint region from the BIOMED-2 protocol. Our results showed that 19 out of 100 cases were t(11;14) positive. It was reported that the positive rates of t(11;14) translocation analyzed by general and semi-nested PCR in MCL were 25.81% and 35.48%, respectively([@ref6]). In the present study, patients older than age of 55 years appeared to be more likely to carry the t(11;14)(q13;q32). The increase in the incidence of the t(11;14) translocation with age in adults has been confirmed elsewhere ([@ref2]). In conclusion, our findings show an accurate detection of t(11;14) translocation by using PCR with one series of breakpoint (BIOMED2 protocol), which is useful to assess an appropriate initial therapy and the neoplasms' management. Hence, further investigations with new set of molecular categories are required to assess possible correlations with clinical data and offer a better understanding of the biology, diagnostic and treatment of this neoplasia.
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